Logo image of NMTR

9 METERS BIOPHARMA INC (NMTR) Stock Fundamental Analysis

USA - NASDAQ:NMTR - US6544052086 - Common Stock

0.0722 USD
-0.05 (-42.97%)
Last: 7/25/2023, 8:00:02 PM
0.093 USD
+0.02 (+28.81%)
After Hours: 7/25/2023, 8:00:02 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NMTR. NMTR was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NMTR have multiple concerns. NMTR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NMTR has reported negative net income.
NMTR had a negative operating cash flow in the past year.
In the past 5 years NMTR always reported negative net income.
In the past 5 years NMTR always reported negative operating cash flow.
NMTR Yearly Net Income VS EBIT VS OCF VS FCFNMTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

The profitability ratios for NMTR are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NMTR Yearly ROA, ROE, ROICNMTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NMTR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMTR Yearly Profit, Operating, Gross MarginsNMTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

0

2. Health

2.1 Basic Checks

NMTR has more shares outstanding than it did 1 year ago.
The debt/assets ratio for NMTR is higher compared to a year ago.
NMTR Yearly Shares OutstandingNMTR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
NMTR Yearly Total Debt VS Total AssetsNMTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -50.22, we must say that NMTR is in the distress zone and has some risk of bankruptcy.
NMTR has a worse Altman-Z score (-50.22) than 95.31% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -50.22
ROIC/WACCN/A
WACCN/A
NMTR Yearly LT Debt VS Equity VS FCFNMTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

NMTR has a Current Ratio of 0.59. This is a bad value and indicates that NMTR is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.59, NMTR is doing worse than 92.96% of the companies in the same industry.
A Quick Ratio of 0.59 indicates that NMTR may have some problems paying its short term obligations.
NMTR's Quick ratio of 0.59 is on the low side compared to the rest of the industry. NMTR is outperformed by 91.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.59
NMTR Yearly Current Assets VS Current LiabilitesNMTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for NMTR have decreased by -8.12% in the last year.
EPS 1Y (TTM)-8.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NMTR will show a very strong growth in Earnings Per Share. The EPS will grow by 33.03% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.27%
EPS Next 2Y27%
EPS Next 3Y18.37%
EPS Next 5Y33.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMTR Yearly Revenue VS EstimatesNMTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2023 2026 2027 2028 2029 2030 100M 200M 300M 400M
NMTR Yearly EPS VS EstimatesNMTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NMTR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMTR Price Earnings VS Forward Price EarningsNMTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMTR Per share dataNMTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

NMTR's earnings are expected to grow with 18.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27%
EPS Next 3Y18.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NMTR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

9 METERS BIOPHARMA INC

NASDAQ:NMTR (7/25/2023, 8:00:02 PM)

After market: 0.093 +0.02 (+28.81%)

0.0722

-0.05 (-42.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-15 2023-05-15/amc
Earnings (Next)08-14 2023-08-14/bmo
Inst Owners0%
Inst Owner Change0%
Ins Owners3.91%
Ins Owner Change0%
Market Cap1.04M
Revenue(TTM)N/A
Net Income(TTM)-46.28M
Analysts80
Price Target10.58 (14553.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.44%
Min EPS beat(2)-28.53%
Max EPS beat(2)-18.34%
EPS beat(4)2
Avg EPS beat(4)-6.77%
Min EPS beat(4)-28.53%
Max EPS beat(4)13.92%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-49.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.93%
EPS NY rev (1m)44.63%
EPS NY rev (3m)44.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.46
EYN/A
EPS(NY)-1.25
Fwd EYN/A
FCF(TTM)-2.6
FCFYN/A
OCF(TTM)-2.6
OCFYN/A
SpS0
BVpS-0.44
TBVpS-0.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.59
Altman-Z -50.22
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)66.06%
Cap/Depr(5y)59.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.5%
EPS Next Y58.27%
EPS Next 2Y27%
EPS Next 3Y18.37%
EPS Next 5Y33.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year64.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.86%
OCF growth 3YN/A
OCF growth 5YN/A

9 METERS BIOPHARMA INC / NMTR FAQ

What is the ChartMill fundamental rating of 9 METERS BIOPHARMA INC (NMTR) stock?

ChartMill assigns a fundamental rating of 0 / 10 to NMTR.


Can you provide the valuation status for 9 METERS BIOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to 9 METERS BIOPHARMA INC (NMTR). This can be considered as Overvalued.


Can you provide the profitability details for 9 METERS BIOPHARMA INC?

9 METERS BIOPHARMA INC (NMTR) has a profitability rating of 0 / 10.


What is the earnings growth outlook for 9 METERS BIOPHARMA INC?

The Earnings per Share (EPS) of 9 METERS BIOPHARMA INC (NMTR) is expected to grow by 58.27% in the next year.